What is Sofie Biosciences?
Sofie Biosciences is a specialized healthcare technology firm dedicated to revolutionizing clinical diagnostics and therapeutics through the application of molecular imaging. The company operates at the intersection of biology and technology, providing a comprehensive suite of imaging and radiochemistry systems. By integrating a premier radiopharmacy network with contract manufacturing capabilities, Sofie Biosciences removes traditional barriers to entry for theranostic technologies. This integrated approach allows healthcare providers to better understand and treat the underlying biology of disease, ultimately improving patient outcomes through more precise, accessible diagnostic tools.
How much funding has Sofie Biosciences raised?
Sofie Biosciences has raised a total of $55.6M across 6 funding rounds:
Series A
$5M
Grant
$1.5M
Private Equity
$3.7M
Series B
$16M
Debt
$2M
Series C
$27.4M
Series A (2013): $5M with participation from Tata Industries, MRM Capital, and Cycad Group
Grant (2014): $1.5M led by Cycad Group and MRM Capital
Private Equity (2016): $3.7M supported by Artiman Managment, LLC
Series B (2018): $16M featuring Mayor Richard Riordan
Debt (2020): $2M backed by PPP
Series C (2020): $27.4M with participation from Jubilant Pharma Limited
Key Investors in Sofie Biosciences
Artiman Managment, LLC
Artiman Management LLC is an investment firm that focuses on innovative companies in various sectors, supporting businesses that leverage technology to improve healthcare and diagnostics.
Tata Industries
Tata Industries is part of a prominent global conglomerate with a focus on innovation and industrial growth, providing strategic backing to companies that align with their diverse technological interests.
Cycad Group
Cycad Group is a venture capital firm focused on investing in technology across various sectors, including healthcare and energy, with a strategy emphasizing cutting-edge solutions for unmet market needs.
What's next for Sofie Biosciences?
With the support of its latest capital, Sofie Biosciences is well-positioned to accelerate the adoption of its theranostic platforms across global markets. The company is expected to focus on expanding its radiopharmacy footprint and enhancing its contract manufacturing organization (CMO) services to meet the rising demand for novel diagnostic agents. As the firm moves beyond its current lifecycle stage, strategic priorities will likely include the commercialization of next-generation imaging systems and the deepening of its partnerships within the oncology and neurology sectors. By maintaining its focus on reducing the cost and complexity of molecular imaging, Sofie Biosciences is poised to remain a pivotal player in the evolution of precision medicine.
See full Sofie Biosciences company page
